Payment overview · 2025
General Payments
$538.18
28 reported records · 13 companies
Healthcare provider profile · identity verified
Elizabeth Saft, DO
Allopathic & Osteopathic Physicians|Family Medicine · ETOWAH, NC · NPI 1265627574
Verified facts
What the public records show
CMS Open Payments records show Elizabeth Saft, DO received $538.18 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.96 | 25.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.73 | 18.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.99 | 10.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $52.05 | 9.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.93 | 6.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.02 | 5.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.19 | 5.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.74 | 3.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.31 | 3.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $18.00 | 3.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.98 | 3.2% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $16.56 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.72 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.18 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $101.26 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $98.73 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.35 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $87.35 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $69.41 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $53.99 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.70 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.32 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.02 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $27.19 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 187 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 31 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
157 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
187 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 568 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 120 |
| Lisinopril | Lisinopril | 339 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 339 | 97 |
| Losartan Potassium | Losartan Potassium | 323 | 102 |
| Gabapentin | Gabapentin | 317 | 88 |
| Omeprazole | Omeprazole | 317 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 300 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 270 | 64 |
| Trazodone Hcl | Trazodone Hcl | 245 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 218 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 64 |
| Metformin Hcl Er | Metformin Hcl | 208 | 55 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 207 | 60 |
| Eliquis | Apixaban | 187 | 43 |
| Furosemide | Furosemide | 180 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 177 | 16 |
| Montelukast Sodium | Montelukast Sodium | 169 | 54 |
| Lorazepam | Lorazepam | 168 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 157 | 25 |
| Pregabalin | Pregabalin | 145 | 21 |
| Metformin Hcl | Metformin Hcl | 143 | 39 |
| Sertraline Hcl | Sertraline Hcl | 137 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 23 |
| Ozempic | Semaglutide | 127 | 24 |
| Simvastatin | Simvastatin | 122 | 37 |
| Spironolactone | Spironolactone | 121 | 32 |
| Meloxicam | Meloxicam | 113 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 35 |
| Buspirone Hcl | Buspirone Hcl | 108 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 39 |
| Bupropion Xl | Bupropion Hcl | 102 | 32 |
| Famotidine | Famotidine | 102 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 14 |
| Alprazolam | Alprazolam | 92 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 29 |
| Clonazepam | Clonazepam | 85 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 28 |
| Tramadol Hcl | Tramadol Hcl | 82 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 24 |
| Celecoxib | Celecoxib | 77 | 22 |
| Finasteride | Finasteride | 77 | 24 |
| Carvedilol | Carvedilol | 75 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 19 |
| Promethazine Hcl | Promethazine Hcl | 67 | 13 |
| Alendronate Sodium | Alendronate Sodium | 65 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 63 | suppressed |
| Estradiol | Estradiol | 63 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 15 |
| Potassium Chloride | Potassium Chloride | 62 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 11 |
| Nystatin | Nystatin | 57 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 14 |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Atenolol | Atenolol | 51 | 13 |
| Glipizide | Glipizide | 51 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 50 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 13 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Glipizide Er | Glipizide | 46 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 11 |
| Ondansetron Odt | Ondansetron | 45 | suppressed |
| Cephalexin | Cephalexin | 43 | 28 |
| Allopurinol | Allopurinol | 42 | 16 |
| Benazepril Hcl | Benazepril Hcl | 42 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 16 |
| Synthroid | Levothyroxine Sodium | 41 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 39 | 15 |
| Lamotrigine | Lamotrigine | 38 | 12 |
| Methylprednisolone | Methylprednisolone | 38 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 11 |
| Belsomra | Suvorexant | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Jardiance | Empagliflozin | 31 | 12 |
| Prednisone | Prednisone | 31 | 19 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Diazepam | Diazepam | 29 | 11 |
| Fluconazole | Fluconazole | 29 | 23 |
| Valacyclovir | Valacyclovir Hcl | 28 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 19 |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 11 |
| Azithromycin | Azithromycin | 20 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 12 |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Ramelteon | Ramelteon | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.18 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AJOVY, AUSTEDO XR, BREZTRI, CAPLYTA, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, EVENITY, FANAPT, FARXIGA, FLOWTRIEVER CATHETER, S, JARDIANCE, Kerendia, NEXIUM, NURTEC ODT, REXULTI, Symbravo, TRELEGY ELLIPTA, VOQUEZNA, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error